Dianthus Therapeutics (DNTH) counsel exercises 15,000 stock options at $18.17
Rhea-AI Filing Summary
Dianthus Therapeutics, Inc. insider activity: Adam M. Veness, SVP, General Counsel and Secretary, reported exercising stock options for 15,000 shares of common stock on August 13, 2026 at an exercise price of $18.17 per share. This converted a stock option into directly held common shares.
The derivative position of 15,000 option shares was disposed of upon exercise, leaving Veness with 73,240 derivative securities reported following the transaction. The option award vested 25% on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 15,000 shares
Net Buy
2 txns
Insider
Veness Adam M
Role
SVP, General Counsel and Sec.
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1 | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,000 | $18.17 | $273K |
Holdings After Transaction:
Stock Option (Right to Buy) — 73,240 shares (Direct);
Common Stock — 15,000 shares (Direct)
Footnotes (1)
- F1. The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Options Exercised: 15,000 shares
Exercise Price: $18.17 per share
Derivative Holdings After Exercise: 73,240 securities
+4 more
7 metrics
Options Exercised
15,000 shares
Stock option (right to buy) exercised on August 13, 2026
Exercise Price
$18.17 per share
Exercise or conversion price for the 15,000 stock options
Derivative Holdings After Exercise
73,240 securities
Total derivative securities reported following the option exercise
Common Shares From Exercise
15,000 shares
Common stock held directly after option exercise transaction
Option Expiration Date
June 28, 2033
Expiration date of the stock option prior to exercise
Initial Vesting Date
June 20, 2024
25% of the option vested on this date
Remaining Vesting Period
3 years
Remaining 75% vests in equal monthly installments over three years
Key Terms
Stock Option (Right to Buy), derivative security, vesting, exercise price
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"underlying this stock option award vested as to 25% of the shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion or exercise price: 18.1700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What insider transaction did DNTH executive Adam M. Veness report?
Adam M. Veness reported exercising stock options for 15,000 shares of Dianthus Therapeutics common stock on August 13, 2026 at $18.17 per share, converting a derivative position into directly held common shares.
How many DNTH stock options did Adam M. Veness exercise and at what price?
He exercised 15,000 stock options, acquiring 15,000 shares of common stock at an exercise price of $18.17 per share. The exercise eliminated the corresponding option position tied to those shares.
What are Adam M. Veness’s reported holdings after the DNTH option exercise?
Following the transactions, one line shows 73,240 derivative securities remaining after the option exercise, and another shows 15,000 shares of common stock held directly, reflecting the newly acquired shares from the exercised options.
How does the DNTH stock option granted to Adam M. Veness vest?
The option vests 25% on June 20, 2024, with the remaining 75% vesting in equal monthly installments over the next three years, subject to his continued service to Dianthus Therapeutics on each vesting date.
Was the DNTH Form 4 transaction by Adam M. Veness a market sale or purchase?
The Form 4 reports a derivative exercise, not an open-market trade. Stock options were converted into 15,000 common shares at $18.17 per share, with no separate sale transaction reported in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
